VCIM
LYEL icon

Velan Capital Investment Management’s Lyell Immunopharma LYEL Stock Holding History

Velan Capital Investment Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.05M Buy
+102,000
New +$2.38M 1.28% 21

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Velan Capital Investment Management's LYEL Position: Q1 2026 in Review

Velan Capital Investment Management opened a new position in Lyell Immunopharma (LYEL) in Q1 2026: 102,000 shares worth $2.05M. The stake represents 1.28% of the portfolio and ranks #21 among its holdings.

74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Velan Capital Investment Management held 102,000 shares of Lyell Immunopharma worth $2.05M as of Q1 2026.
  • Lyell Immunopharma was a new Velan Capital Investment Management position in Q1 2026.
  • Lyell Immunopharma made up 1.28% of Velan Capital Investment Management's portfolio in Q1 2026, its #21 holding.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.